It has been previously demonstrated that vitamin A and its analog can affect the transcriptional activity of the ADAM10 promoter and enhance the nonamyloidogenic sAPPα secretion pathway, which may act as a potential therapeutic target for AD (Tippmann et al., 2009). The gene discussed is ADAM10; the disease is Alzheimer disease.